5-Aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICAR) enhances the efficacy of rapamycin in human cancer cells

Apoptotic effects of high-dose rapamycin occur in S-phase of the cell cycle

(2015) Mahesh Saqcena et al.   CELL CYCLE

Reciprocal Regulation of AMP-activated Protein Kinase and Phospholipase D

(2015) Suman Mukhopadhyay et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phospholipase D and the Maintenance of Phosphatidic Acid Levels for Regulation of Mammalian Target of Rapamycin (mTOR)

(2014) David A. Foster et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Use of Metformin Alone Is Not Associated with Survival Outcomes of Colorectal Cancer Cell but AMPK Activator AICAR Sensitizes Anticancer Effect of 5-Fluorouracil through AMPK Activation

(2014) Xinbing Sui et al.   PLoS One

Suppression of AKT Phosphorylation Restores Rapamycin-Based Synthetic Lethality in SMAD4-Defective Pancreatic Cancer Cells

(2013) Onica Le Gendre et al.   MOLECULAR CANCER RESEARCH

Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate

(2012) Patrick S. Ward et al.   CANCER CELL

Adverse events associated with mTOR inhibitors

(2012) Nicolas Pallet et al.   Expert Opinion On Drug Safety

mTOR signaling: PLD takes center stage

(2011) Yuting Sun et al.   CELL CYCLE

Targeting mTOR with rapamycin: One dose does not fit all

(2011) David A. Foster et al.   CELL CYCLE

High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1

(2011) Paige Yellen et al.   CELL CYCLE

Targeting the mTOR kinase domain: the second generation of mTOR inhibitors

(2011) Yan-Jie Zhang et al.   DRUG DISCOVERY TODAY

A phase I study of temsirolimus and metformin in advanced solid tumours

(2010) Mary J. MacKenzie et al.   INVESTIGATIONAL NEW DRUGS

The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation

(2008) Ralph J. DeBerardinis et al.   Cell Metabolism

Regulation of mTORC1 and mTORC2 Complex Assembly by Phosphatidic Acid: Competition with Rapamycin

(2008) A. Toschi et al.   MOLECULAR AND CELLULAR BIOLOGY

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

(2008) Tim F Cloughesy et al.   PLOS MEDICINE